| Objective To investigate whether miR-214 can regulate BMP-2 and Smad4 in osteoporosis. Methods The Rats were divided into two groups (control group, surgery group), the surgery treatment of osteoporosis rats model was established, and the related factor in serum of two groups of rats, bone density, femur dyeing for pathology observation, at the same time each group of rat bone marrow mesenchymal stem cells (BMSCs) were cultured in vitro, and the expression levels of miR-214 were detected by qPCR, and the expression levels of BMP-2 and Smad4 related proteins were detected by Western blot.Rat osteoblasts were cultured in vitro and divided into 3 groups (control group, overexpressed group and inhibited group). miR-214 mimics and anti-miR-214 were transfected into the overexpressed group and the inhibited group, respectively. The proliferation ability, apoptosis, and expression levels of BMP-2 and smad4-related proteins in rat osteoblasts in each group were tested. Results Compared with the sham group, serum calcium, alkaline phosphatase (ALP) concentration and bone mineral density (BMD) of the rats in the operation group were significantly decreased, and serum phosphorus content was significantly increased, with statistically significant differences(P<0.05).Meanwhile, the BMSCs ALP content in the sham group was significantly higher than that in the operation group. Compared with the BMSCs of the surgery group and the sham surgery group, the expression of mirR-214 in the cells was significantly increased, with statistically significant differences (P<0.05).Detection of each rat osteoblast after transfection, compared with control group, the expression group cell proliferation capacity decreased obviously, cell apoptosis was significantly increased, BMP-2 and Smad4 expression levels, and inhibiting group increased cell proliferation, apoptosis, a significant reduction in BMP-2 and Smad4 expression levels, statistically significant difference (P<0.05).Conclusion miR-214 may inhibit the proliferation of osteoblasts by targeting BMP-2 and Smad4, leading to the occurrence or development of osteoporosis. |